147 related articles for article (PubMed ID: 10114004)
1. Drug usage evaluation: H2-receptor antagonist use in 30 hospitals.
Kowalsky SF; Hamilton RA; Figge HL
Hosp Formul; 1991 Sep; 26(9):725-6, 732, 734-6 passim. PubMed ID: 10114004
[TBL] [Abstract][Full Text] [Related]
2. Effects of three H2-receptor antagonists (cimetidine, famotidine, ranitidine) on serum gastrin level.
Ohsawa T; Hirata W; Higichi S
Int J Clin Pharmacol Res; 2002; 22(2):29-35. PubMed ID: 12503773
[TBL] [Abstract][Full Text] [Related]
3. Clinical review of histamine2 receptor antagonists.
Lipsy RJ; Fennerty B; Fagan TC
Arch Intern Med; 1990 Apr; 150(4):745-51. PubMed ID: 1970232
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy of cimetidine, famotidine, ranitidine, and mylanta in postoperative stress ulcers. Gastric pH control and ulcer prevention in patients undergoing coronary artery bypass graft surgery.
Lamothe PH; Rao E; Serra AJ; Castellano J; Woronick CL; McNicholas KW; Lemole GM
Gastroenterology; 1991 Jun; 100(6):1515-20. PubMed ID: 2019357
[TBL] [Abstract][Full Text] [Related]
5. Pretreatment H2 receptor antagonists that differ in P450 modulation activity: comparative effects on paclitaxel clearance rates and neutropenia.
Slichenmyer WJ; Donehower RC; Chen TL; Bowling MK; McGuire WP; Rowinsky EK
Cancer Chemother Pharmacol; 1995; 36(3):227-32. PubMed ID: 7781143
[TBL] [Abstract][Full Text] [Related]
6. Use of i.v. cimetidine, ranitidine, and famotidine in 40 hospitals.
Segal R; Russell WL; Oh T; Ben-Joseph R
Am J Hosp Pharm; 1993 Oct; 50(10):2077-81. PubMed ID: 8238052
[TBL] [Abstract][Full Text] [Related]
7. Risk for adverse events among patients receiving intravenous histamine2-receptor antagonists.
Ben-Joseph R; Segal R; Russell WL
Ann Pharmacother; 1993 Dec; 27(12):1532-7. PubMed ID: 8305790
[TBL] [Abstract][Full Text] [Related]
8. Do H2 receptor antagonists have a therapeutic role in childhood?
Kelly DA
J Pediatr Gastroenterol Nutr; 1994 Oct; 19(3):270-6. PubMed ID: 7815256
[TBL] [Abstract][Full Text] [Related]
9. Does H2 receptor antagonist-resistant ulcer exist?--A review based on bioavailability in man.
Kawai K
Gastroenterol Jpn; 1992 Jun; 27(3):418-23. PubMed ID: 1624085
[TBL] [Abstract][Full Text] [Related]
10. Famotidine, a new, potent, long-acting histamine H2-receptor antagonist: comparison with cimetidine and ranitidine in the treatment of Zollinger-Ellison syndrome.
Howard JM; Chremos AN; Collen MJ; McArthur KE; Cherner JA; Maton PN; Ciarleglio CA; Cornelius MJ; Gardner JD; Jensen RT
Gastroenterology; 1985 Apr; 88(4):1026-33. PubMed ID: 2857672
[TBL] [Abstract][Full Text] [Related]
11. Clinical evaluation of the effect of omeprazole, cimetidine, famotidine and ranitidine on histamine induced cutaneous wheal and flare response.
Saha N; Sachdev A; Bhasin DK; Sankaranahyanan A; Khosla PP; Singh K; Sharma PL
Int J Clin Pharmacol Ther Toxicol; 1993 Jul; 31(7):322-5. PubMed ID: 8103763
[TBL] [Abstract][Full Text] [Related]
12. Implementing therapeutic interchange of intravenous famotidine for cimetidine and ranitidine.
Oh T; Franko TG
Am J Hosp Pharm; 1990 Jul; 47(7):1547-51. PubMed ID: 2114789
[TBL] [Abstract][Full Text] [Related]
13. Adverse reactions to H2-receptor antagonists in Denmark before and after transfer of cimetidine and ranitidine to over-the-counter status.
Andersen M; Schou JS
Pharmacol Toxicol; 1991 Oct; 69(4):253-8. PubMed ID: 1683484
[TBL] [Abstract][Full Text] [Related]
14. Comparison of famotidine with cimetidine and ranitidine.
Berardi RR; Tankanow RM; Nostrant TT
Clin Pharm; 1988 Apr; 7(4):271-84. PubMed ID: 2896559
[TBL] [Abstract][Full Text] [Related]
15. Multi-purpose evaluation of H2-antagonist usage.
Gianarkis D
Hosp Formul; 1992 May; 27(5):527-30, 532. PubMed ID: 10117769
[TBL] [Abstract][Full Text] [Related]
16. Famotidine in the therapy of gastric hypersecretory states.
Vinayek R; Howard JM; Maton PN; Wank SA; Slaff JI; Gardner JD; Jensen RT
Am J Med; 1986 Oct; 81(4B):49-59. PubMed ID: 2877575
[TBL] [Abstract][Full Text] [Related]
17. Use of H2-receptor antagonists in children.
Dimand RJ
DICP; 1990 Nov; 24(11 Suppl):S42-6. PubMed ID: 2270695
[TBL] [Abstract][Full Text] [Related]
18. Retrospective analysis of formulary restriction demonstrates significant cost savings.
Wetmore RW; Jennings RH
Hosp Formul; 1991 Nov; 26 Suppl D():30-2. PubMed ID: 10136564
[TBL] [Abstract][Full Text] [Related]
19. Morning versus evening dose: a comparison of three H2-receptor blockers in duodenal ulcer healing.
Khasawneh SM; Affarah HB
Am J Gastroenterol; 1992 Sep; 87(9):1180-2. PubMed ID: 1519576
[TBL] [Abstract][Full Text] [Related]
20. Gastroesophageal reflux and histamine2 antagonists.
Bell SG
Neonatal Netw; 2003; 22(2):53-7. PubMed ID: 12696725
[No Abstract] [Full Text] [Related]
[Next] [New Search]
